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eChoGpl  Choline ether phospholipid
eEtnGpl  Ethanolamine ether phospholipid
HPLC  High-performance liquid chromatography
LC  Liquid chromatography
LysoPlsEtn  Lyso-ethanolamine plasmalogen
LysoPtdCho  Lysophosphatidylcholine





PLA1  Phospholipase A1
PlsCho  Choline plasmalogen




Ether phospholipids constitute a special class of phospho-
lipids characterized by the presence of ether bonds at the 
sn-1 position of the glycerol backbone. There are two types 
of ether bonds in ether phospholipids: alkyl bonds and 
alkenyl bonds. Phospholipids with an alkenyl bond (vinyl 
ether bond) are called plasmalogens [1–5]. Ether phos-
pholipids are found in almost all mammalian tissues, and 
plasmalogens constitute about 18–20 % of the total phos-
pholipids in cell membranes [1]. Ethanolamine ether phos-
pholipids (eEtnGpl) are much more abundant than choline 
ether phospholipids (eChoGpl) in animal tissues except 
heart and skeletal muscle [1, 4]. Plasmalogens are not only 
structural component of mammalian cell membranes and a 
reservoir for second messengers but also may be involved 
in membrane fusion, ion transport, and cholesterol efflux 
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[1–5]. The vinyl ether bond at the sn-1 position makes plas-
malogens more susceptible to oxidative stress than the cor-
responding ester-bonded glycerophospholipids. Therefore, 
plasmalogens may act as antioxidants and protect cells 
from oxidative stress [1, 4, 5].
Ethanolamine ether phospholipids (eEtnGpl) and choline 
ether phospholipids (eChoGpl) are found in human serum 
(plasma), but the relative concentration of the ether phospho-
lipids in the plasma phospholipids are very low as compared 
to those in other tissues such as leukocytes and erythrocytes. 
Functions or physiological roles of ether phospholipids in 
serum (plasma) are not well elucidated, but decreases in plas-
malogens in serum (plasma) have been reported in several dis-
eases such as Alzheimer’s disease [6–9], Parkinson’s disease 
[10], metabolic syndrome [11–13], schizophrenia [14, 15], 
uremic patients [16], and inflammatory bowel disease [17].
Measurement of the ether phospholipids in human 
serum (plasma) has been difficult because of its low con-
centration. Gas chromatography (GC) and/or gas chro-
matography coupled with mass spectrometry (GC/MS) 
has been used for measurement of plasmalogens in serum 
(plasma) by detecting fatty aldehydes (dimethyl acetals) 
[16, 18], but these methods were an indirect assay for plas-
malogens. Nowadays measurement of serum plasmalogens 
seems to depend on liquid chromatography–tandem mass 
spectrometry (LC/MS/MS) [6–9, 17, 19–22]. An HPLC 
method with a flow gamma counter by use of radioactive 
iodine is reported [8, 23]. However, all of these methods 
require expensive apparatus and are time-consuming.
Phospholipase A1 (PLA1) hydrolyzes ester (acyl) bond 
at the sn-1 position of glycerophospholipids, but it does not 
act on ether bond at the sn-1 position. When serum and/or 
plasma is treated with PLA1, all of the diacyl phospholip-
ids are completely hydrolyzed; however, ether phospho-
lipids remain intact. The treatment of plasma with PLA1 
makes eEtnGpl and eChoGpl detectable as independent 
peaks in the HPLC with evaporative light scattering detec-
tion (HPLC–ELSD). The same sample used for the HPLC 
method can be applied to liquid chromatography–electro-
spray ionization mass spectrometry (LC/ESI–MS). HPLC–
ELSD and LC/ESI–MS systems are generally less expen-
sive and are easier to maintain than those of LC/MS/MS.
Materials and Methods
Materials
Phospholipase A1 from Thermomyces lanuginosus expressed 
in Aspergillus orizae was purchased from Sigma-Aldrich 
Co. (Tokyo, Japan). Specific activity of the PLA1 was not 
recorded. PLA1 from A. orizae (10,000–13,000 U/g) was 
purchased from Mitsubishi Kagaku Foods Co. (Tokyo, 
Japan). Phosphatidylethanolamine from egg yolk, phos-
phatidylcholine from bovine liver, and sphingomyelin from 
bovine heart were purchased from Doosan Serdary Res. Lab. 
(Toronto, Canada) through Funakoshi Co. (Tokyo, Japan).
Preparation of Ether Phospholipids in Human Plasma
With informed consent, human venous blood of volun-
teers who were aged over 70 years (male 13, female 29; 
age 76 ± 4.6) was drawn into a tube containing heparin, 
and plasma was separated by using a clinical centrifuge at 
1000g for 5 min. Plasma was kept at −80 °C until use. PLA1 
(Sigma) was diluted with an equal volume of 0.1 M citrate 
buffer (pH 4.5), and 20 μL of the diluted PLA1 was added to 
80 μL of plasma and incubated at 45 °C for 60 min.
Extraction of Lipids
Lipid extraction after the treatment of plasma with PLA1 
was done according to the reported method [24]. Eight 
hundred microliters of n-hexane/isopropanol (3:2, v/v) was 
added to the PLA1-treated plasma, and after vigorous mix-
ing, it was placed in an ultrasound bath for 5 min. Then 
400 μL of Na2SO4 solution (1 g of anhydrous Na2SO4 dis-
solved in 15 mL of water) was added and left for 5 min. 
Four hundred microliters of the hexane layer was trans-
ferred to a new conical Eppendorf tube. Then 400 μL of 
hexane/isopropanol (7:2, v/v) was added to the lower phase 
and vigorously mixed, and the hexane layer (300 μL) was 
recovered. The combined hexane layer was dried under N2 
gas and stored at −30 °C until use.
In some experiments a chloroform/methanol (1:2, v/v) 
method was used with some modification from Bligh and 
Dyer’s method [25]. After treatment of plasma with PLA1 
as described, 50 μL of physiological saline solution was 
added. Then 300 μL of chloroform/methanol (1:2, v/v) was 
added, vortexed for 1 min, and sonicated for 1 min. After 
mixing with 100 μL of chloroform, 100 μL of water was 
added. After brief centrifugation, 160 μL of the lower chlo-
roform phase was transferred to a new tube. Lipids were 
re-extracted from the remaining lower phase with 100 μL 
of chloroform, and 100 μL of the lower phase was recov-
ered. The combined chloroform phase was dried under N2 
gas and stored at −30 °C until use.
HPLC–ELSD Method
Separation of phospholipid classes including ether phos-
pholipids by HPLC was done by our reported method [26]. 
The HPLC system was an Agilent 1100 equipped with 
a four-solvent delivery system, a degasser, an automatic 
injector, and evaporative light scattering detector. The col-
umn was a LiChrosphere 100 Diol (250 × 2 mm), 5 μm 
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(Merck, Germany). Mobile phase A was n-hexane/2-pro-
panol/acetic acid (82:17:1, v/v/v) with 0.08 % triethylamine 
(TEA), and mobile phase B was 2-propanol/water/acetic 
acid (85:14:1, v/v/v) with 0.08 % TEA. Mobile phase B 
was 4 % at 0 min, and increased linearly to 37 % in 21 min. 
The gradient continued from 37 to 85 % in 4 min, then 
85 % B was maintained for 1 min. Mobile phase B was 
decreased to 4 % in 3 min and then 4 % B was maintained 
for 7 min to precondition the column ready for the next 
injection. The column temperature was 50 °C and flow rate 
was 0.4 mL/min. The phospholipid classes were detected 
by ELSD (Agilent 1900 Infinity) with the following set-
tings: evaporation temperature, 60 °C; sensitivity gain, 6; 
flow rate of N2 gas, 1 L/min. Nebulizer temperature was 
30 °C. The lipid extract after PLA1 treatment of plasma 
was reconstituted with 200 μL of hexane/isopropanol (3:2, 
v/v), and 20 μL was applied to the HPLC system.
LC–ESI–MS Method
LC separation of phospholipids classes was done according 
to the reported method [27]. A Nucleosil diol 100-5-OH 
column (250 × 3 mm, 5 μm, Machery-Nagel, Germany) 
was used. Mobile phase A was 53 mM formic acid in ace-
tonitrile (pH 4.5) and mobile phase B was 60 mM ammo-
nium formate and 53 mM formic acid in water (pH 3.64). 
The flow rate was 0.5 mL/min with gradient elution of 
90 % A in 0–2 min, 90–70 % A in 2–15 min, 70 % A in 
15–17 min, 70–90 % A in 15–17 min, 90 % A in 5–30 min. 
The column temperature was 50 °C. Detection of phospho-
lipids was done with an ESI mass spectrometer (Agilent 
6120) with selected ion monitoring (SIM) and full scan 
mode (TIC) in negative ionization mode. The selected ions 
for eEtnGpl, eChoGpl, and sphingomyelin (cerPCho) are 
listed in Tables 1 and 2. The SIM ions were selected from 
ions in peaks of eEtnGpl and eChoGpl of human plasma 
with full scan mode, and they were picked up from the 
reports of plasmalogens in human plasma [11–13]. Capil-
lary voltage was 3500 V, scan rate was 1.0/s, nebulizer gas 
was set at 45 psi, gas flow was 10.0 L/min, source tempera-
ture was 350 °C, and full scans were performed from 680 
to 950 m/z. 
The same sample used for the HPLC–ELSD method was 
applied to the LC/ESI–MS method.
Table 1  Selected ions in LC/ESI–MS analysis of ether phospholipids in human plasma
Ion (m/z) Molecular 
species
Ion (m/z) Molecular 
species
eEtnGpl 688.5 eChoGpl 762.5 C16:0/C16:0
[M − H]− 700.5 C16:0/C18:1 C18:0/C16:1 C18:1/C16:0 [M + COOH]− 776.5 C16:0/C17:0
720.5 C16:0/C20:5 778.8
722.5 C16:0/C20:4 786.6 C16:0/C18:2 C18:1/C16:1
724.5 C16:0/C20:3 C18:1/C18:2 787.5
726.5 C18:0/C18:2 C18:1/C18:1 788.6 C16:0/C18:1 C18:0/C16:1
728.5 C18:0/C18:1 800.5 C18:1/C17:1
746.5 C16:0/C22:6 C18:1/C20:5 802.5 C18:0/C17:1 C18:1/C17:0
748.5 C16:0/C22:5 C18:0/C20:5 C18:1/C20:4 803.5
749.5 808.6 C16:0/C20:5
750.6 C16:0/C22:4 C18:0/C20:4 C18:1/C20:3 810.6 C16:0/C20:4
762.5 812.6 C16:0/C20:3 C18:1/C18:2
772.6 C18:1/C22:6 813.6
773.3 814.6 C18:0/C18:2 C18:1/C18:1
774.6 C18:0/C22:6 C18:1/C22:5 816.6 C18:0/C18:1
775.3 828.5
776.7 C18:0/C22:5 C18:1/C22:4 830.6
778.8 C18:0/C22:4 834.6 C16:0/C22:6 C18:1/C20:5
802.5 836.6 C16:0/C22:5 C18:0/C20:5 C18:1/C20:4





1000 Lipids (2016) 51:997–1006
1 3
Acid Hydrolysis of Ether Phospholipids
Acid hydrolysis of ether phospholipids with hydrochloric acid 
(HCl) was done after PLA1 treatment of total lipids [28, 29]. 
Briefly, the dried lipid extract after the treatment with PLA1 
was dissolved in 300 μL of methanol/chloroform/water (2:1:1, 
v/v/v), then 150 μL of 1 N HCl and 150 μL of methanol were 
added. After vigorous mixing, the solution was incubated at 
room temperature for 1 h. Then, 150 μL each of chloroform 
and water were added to the solution. The solution was cen-
trifuged at 1000g for 5 min. The chloroform layer was dried 
under N2 gas (HCl solution method). The acid-hydrolyzed 
lipids were resuspended in hexane/isopropanol (3:2, v/v) and 
subjected to the HPLC–ELSD and LC/ESI–MS methods.
Another acid hydrolysis method for the ether phospho-
lipids was also used [30]. The dried lipids after the treat-
ment with PLA1 in the test tubes were inverted over five 
drops of 12 N HCl for 5 min (HCl fume method) [30]. The 
lipids were extracted with hexane/isopropanol (3:2, v/v) 
as described earlier (“Extraction of Lipids”). Lipids were 
reconstituted in hexane/isopropanol (3:2, v/v) and sub-
jected to the HPLC–ELSD method.
Results and Discussion
Hydrolysis of Plasma with PLA1
The brochure from the provider reported that the optimum 
temperature and optimum pH for PLA1 activity are 45 °C 
and pH 4.5, respectively. Therefore, we diluted PLA1 with 
0.1 M citrate buffer (pH 4.5) and the incubation of plasma 
with PLA1 was done at 45 °C.
Figure 1 shows HPLC–ELSD chromatograms (a) before 
and (b) after the treatment of plasma with PLA1 at 45 °C 
for 60 min. Diacylglycerophospholipids disappeared com-
pletely on treatment with PLA1.
PLA1 purchased from Mitsubishi Kagaku Food Co. was 
suspended in 0.1 M citrate buffer (50 mg/mL). Forty micro-
liters of the enzyme solution was added to 80 μL of plasma 
and incubated at 45 °C for 60 min.
The two different PLA1 which were obtained from dif-
ferent sources were applied to the same human plasma, and 
the results showed identical chromatograms of ESI detec-
tion (Fig. 2a, b).
The time courses of the changes in each main phospho-
lipid in plasma during incubation of plasma with PLA1 
at 45 °C for 60 min are shown in Fig. 3. Phosphatidyl-
choline (PtdCho), which is the most abundant phospho-
lipid in plasma, was hydrolyzed completely within 40 min 
(Fig. 3a). Lysophosphatidylcholine (LysoPtdCho), which 
was the product from hydrolysis of PtdCho by PLA1, 
increased rapidly within 10 min and then decreased gradu-
ally until 50 min (Fig. 3a). On the other hand, ether phos-
pholipids (eEtnGpl and eChoGpl) and sphingomyelin 
(CerPCho) remained unchanged for 60 min incubation at 
45 °C (Fig. 3a). Furthermore, the levels of the ether phos-
pholipids (eEtnGpl and eChoGpl) and sphingomyelin (Cer-
PCho) were constant by incubation with different amounts 
of PLA1 for 60 min at 45 °C (Fig. 3b).
HPLC (LC) Method
The HPLC–ELSD method can separate eEtnGpl and 
eChoGpl as well as all other phospholipids classes usually 
found in mammalian tissues by a single chromatographic 
Table 2  Selected ions of PtdEtn, PtdCho, and CerPCho for standard curve for LC/ESI–MS
Ion (m/z) Molecular species Ion (m/z) Molecular species lon (m/z)
PtdEtn 714.5 C16:0/C18:2 CerPCho 719.5 C14:0 745.6
[M − H]− 716.5 C16:0/C18:1 [M + COOH]− 747.5 C16:0 746.5
738.5 C16:0/C20:4 C18:2/C18:2 749.5 C16:1 748.5
742.5 C18:0/C18:2 C18:1/C18:1 C16:0/C20:2 775.3 C18:0 776.7
744.5 C18:0/C18:1 773.3 C18:1 802.5
764.5 C18:1/C20:4 C16:0/C22:5 C18:0/C20:5 771.3 C18:2 816.6
766.5 C18:0/C20:4 C16:0/C22:4 803.5 C20:0 830.6
831.5 C22:0 843.6
829.6 C22:1 845.6
PtdCho 802.5 C16:0/C18:2 859.3 C24:0 860.6
[M + COOH]− 804.5 C16:0/C18:1 857.6 C24:1 935.1
830.5 C18:0/C18:2 C18:1/C18:1 C16:0/C20:2 855.6 C24:2
832.5 C18:0/C18:1 858.3
854.5 C18:1/C20:4 C16:0/C22:5 C18:0/C20:5 720.5
856.5 C18:0/C20:4 C16:0/C22:4 733.5
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run [26]. However, in the case of human plasma, the HPLC 
can separate ethanolamine ether phospholipids (eEtnGpl) 
from phosphatidylethanolamine (PtdEtn), but separation of 
choline ether phospholipid (eChoGpl) from phosphatidyl-
choline (PtdCho) was incomplete, because human plasma 
contains exceptionally high amounts of phosphatidylcho-
line as compared to the other tissues (Fig. 1a).
Treatment of plasma with PLA1 afforded eChoGpl as 
an independent peak and made quantification of eChoGpl 
with the HPLC method more accurate (Fig. 1b). The PLA1 
treatment of plasma did not hydrolyze sphingomyelin as 
well as the ether phospholipids (Fig. 1b); therefore, we 
also quantified sphingomyelin (CerPCho) in parallel with 
eEtnGpl and eChoGpl. Authentic sphingomyelin as well 
as plasma sphingomyelin showed two large peaks by the 
HPLC–ELSD method (Fig. 1).
Any HPLC methods which can separate EtnGpl, Chol-
Gpl, and CerPCho can be used for the present method, 
because the treatment of plasma with PLA1 leaves only 
ether phospholipids and sphingomyelin. The HPLC method 
used for LC/ESI–MS was different from that of the HPLC–
ELSD method, because we were advised by the manufac-
turer of the ESI system that use of trimethylamine (TEA) 
in the mobile phase of ESI detection should be avoided as 
much as possible. Detection of ether phospholipids with 
ESI increases sensitivity as compared to that with ELSD 
(Figs. 1, 2). We monitored both selected ion monitor-
ing (SIM) and full scan mode (TIC) in negative ioniza-
tion mode in the LC/ESI–MS method. The peak shapes 
were almost identical in TIC and SIM, but the baselines of 
Fig. 1  HPLC–ELSD chromatograms of a total phospholipids of 
human plasma, b after phospholipase A1 (PLA1) treatment of plasma, 
c after acid hydrolysis of PLA1-treated plasma. LysoPlsEtn, which 
was a product of acid hydrolysis of PlsEtn, was observed. Lipids 
were extracted with chloroform/methanol (1:2, v/v). PtdEtn phos-
phatidylethanolamine, PtdCho phosphatidylcholine, PtdIns phos-
phatidylinositol, LysoChoGpl lysophosphatidylcholine, eEtnGpl etha-
nolamine ether phospholipid, eChoGpl choline ether phospholipids, 
PakCho choline alkylacylphospholipid, PakEtn ethanolamine alkyla-
cylphospholipid
Fig. 2  LC–ESI–MS chromatograms of plasma treated with PLA1 
from a Sigma Co, b Mitubishi Kagaku Food Co. The same human 
plasma was used for hydrolysis with PLA1 from different sources. 
All of the peak areas and shapes were identical. Total ion current 
mode (TIC) and selected ion mode (SIM) are shown, but the baseline 
of SIM was clearer than that of TIC. For abbreviations, see Fig. 1
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chromatograms from the SIM mode were clearer than those 
from the TIC mode (Fig. 2). Therefore, data from the SIM 
mode were used for calculation of phospholipids (Table 2).
Because standard curves for phospholipids by detec-
tion with ELSD do not show linearity [31–33], we used 
lineal regression curves (R2 > 0.97) for calculation, and 
eEtnGpl and eChoGpl were calculated as PtdEtn and Ptd-
Cho, respectively (Fig. 4). For calculation in micromolar 
units, the following molecular weight (MW) was used: 
PtdCho = 790.2, PtdEtn = 748.1, CerPCho = 703. The 
amounts of ether phospholipids in human plasma deter-
mined by the present methods are shown in Table 3. The 
ranges of values of eEtnGpl and eChoGpl were in accord-
ance with the reported values [8, 22, 23]. Data of eEtnGpl 
and eChoGpl from ELSD detection were almost identi-
cal to those from ESI detection. However, the mean value 
of CerPCho from ELSD was lower than that of LC/MS 
(Table 3). These discrepancies may be caused by the dif-
ference of detection method (ELSD and ESI). We learned 
from our experiences that peak areas by ELSD detection 
change considerably with differences of gain, nebulizer 
temperature, or evaporation temperature. 
Lipid Extraction
The recoveries of lysophospholipids were different accord-
ing to the lipid extraction method. The chloroform/metha-
nol method retained large amounts of lysophospholipids 
(Figs. 1, 5a), but the hexane/isopropanol method (3:2, v/v) 
removed almost all of the lysophospholipids (Fig. 5b). 
However, the amounts of the ether phospholipids and 
sphingomyelin were not different between the two methods 
(Fig. 5).
Presence of Alkylacylphospholipids in Human Plasma
To our knowledge, few reports have mentioned the pres-
ence of alkylacylphospholipids in human plasma or 
Fig. 3  a Time courses of main phospholipids in human plasma dur-
ing 60 min incubation with PLA1. PtdCho was completely hydro-
lyzed within 40 min. LysoPtdCho decreased gradually until 50 min 
after rapid increase within 10 min. However, ePtdEtn, ePtdCho, and 
CerPCho remained unchanged for 60 min. Lipids were extracted with 
chloroform/methanol (2:1, v/v). b Levels of the ether phospholipids 
and CerPCho were constant with different amounts of PLA1 during 
60 min incubation at 45 °C. Values are the mean of duplicated deter-
minations. See Fig. 1 for other abbreviations
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serum. After the hydrolysis of plasma with PLA1, sam-
ples were further hydrolyzed with HCl (HCl solution 
method). We found that some of the peaks of ether phos-
pholipids remained after the hydrolysis with HCl in all 
of the six samples examined (Fig. 1c), indicating that 
part of the ether phospholipids in human plasma is alky-
lacylphospholipids (PakEtn and PakCho). Furthermore, 
LysoPlsEtn, which was a product of acid hydrolysis of 
PlsEtn, was observed in the chromatograms (Figs. 1c, 
6b) Because sphingomyelin was not changed by the 
acid hydrolysis, each area of the ether phospholipids 
(eChoGpl and eEtnGpl) and each area of PakEtn and 
PakCho were calculated on the basis of sphingomyelin 
(Table 3). PakCho was indicated to represent more than 
60 % (67.5 ± 3.5 %, n = 6) of choline ether phospho-
lipids (eChoGpl) by ESI detection, and it was indicated 
to represent more than 50 % (55.9 ± 2.7 %, n = 6) by 
ELSD detection. We also detected PakEtn: (19.8 ± 3.3 %, 
n = 6) by ESI and (15.3 ± 5.0 %, n = 6) by ELSD. The 
presence of alkylacylphospholipids in human plasma was 
also confirmed by another acid hydrolysis method of ether 
phospholipid by using fumes of 12 N HCl for 5 min (HCl 
fume method) [30]. Amounts of PakCho detected after the 
HCl fume method were almost the same as those after the 
HCl solution method by detection with ELSD (Table 4); 
however, amounts of PakEtn detected after the HCl fume 
method were much lower than that after the HCl solution 
method (Table 4). Furthermore, no PakEtn was detected 
in three samples out of six samples after the HCl fume 
method.
Fig. 4  Standard curves for diacylphospholipids (PtdEtn, PtdCho) and sphingomyelin (CerPCho) for ELSD detection and ESI detection. All lin-
ear regressions (R2) were above 0.97. See Fig. 1 for abbreviations
Table 3  Amounts of ether phospholipids and sphingomyelin in 
human plasma (μM)
Values are mean ± standard deviation (n = 42)
LC/ESI–MS HPLC–ELSD
eEtnGpl 65.1 ± 29.8 62.1 ± 19.1
eChoGpl 65.9 ± 15.1 75.3 ± 22.4
CerPCho 326.3 ± 74.4 228.2 ± 48.3
1004 Lipids (2016) 51:997–1006
1 3
Conclusion
We developed an HPLC–ELSD method for measurement 
of ether phospholipids in human plasma after hydrolysis 
of plasma with PLA1. The same sample can be used for 
both HPLC–ELSD and LC/ESI–MS. The HPLC–ELSD 
and LC/ESI–MS systems are generally less expensive and 
much easier to maintain than LC/MS/MS. Any HPLC 
Fig. 5  Apparent differences of lysophospholipids by the different lipid extraction methods. a Chloroform/methanol (1:2, v/v) method. b Hex-
ane/isopropanol (3:2, v/v) method. Samples (plasma) used were different from each other. For abbreviations, see Fig. 1
Fig. 6  LC chromatograms with 
ESI detection. a Chromatogram 
of plasma after hydrolysis with 
PLA1. b Chromatogram after 
acid hydrolysis of PLA1-treated 
plasma. Peak of lyso-ethanol-
amine plasmalogen (LysoPl-
sEtn) which was a product of 
acid hydrolysis of PlsEtn was 
observed. For abbreviations, see 
Fig. 1
Table 4  Alkylacylphospholipids in human plasma detected by differ-
ent methods (% of each ether phospholipid)
Values are mean ± standard deviation (n = 6)
HCI solution method HCI fume method
LC–ESI–MS HPLC–ELSD HPLC–ELSD
PakEtn 19.8 ± 5.2 15.3 ± 5.0 8.8 ± 9.9
PakCho 67.5 ± 3.3 55.9 ± 2.8 59.2 ± 12.9
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method which can separate PtdEtn, PtdCho, and CerPCho 
can be used for the present methodology, because treat-
ment of sample with PLA1 leaves only ether phospho-
lipids and sphingomyelin. Furthermore, the presence of 
alkylacylphospholipids (PakEtn and PakCho) in human 
plasma was observed by sequential hydrolysis of plasma 
with PLA1 and HCl. These methodologies including the 
method for differentiation of phospholipid subclasses may 
be applied to tissues other than human plasma.
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